UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score

British journal of dermatology (1951), 2012-05, Vol.166 (5), p.971-975

2012

Volltextzugriff (PDF)

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

Annals of the Rheumatic Diseases, 2010-07, Vol.69 (7), p.1269-1274

2010

Volltextzugriff (PDF)

The impact of skin damage due to cutaneous lupus on quality of life

British journal of dermatology (1951), 2014-02, Vol.170 (2), p.315-321

2014

Volltextzugriff (PDF)

Biological therapies in the treatment of cutaneous lupus erythematosus

Lupus, 2017-02, Vol.26 (2), p.115-118

2017

Volltextzugriff (PDF)

TNF-α production in the skin

Archives of Dermatological Research, 2009, Vol.301 (1), p.87-91

2009

Volltextzugriff (PDF)

Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.853-854

2017

Volltextzugriff (PDF)

Importance of recognition and improved treatment for antimelanoma differentiation‐associated protein 5‐associated dermatomyositis

British journal of dermatology (1951), 2017-11, Vol.177 (5), p.1168-1169

2017

Volltextzugriff (PDF)

A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus

British journal of dermatology (1951), 2013-01, Vol.168 (1), p.145-153

2013

Volltextzugriff (PDF)

Cutaneous lupus erythematosus: Diagnosis and treatment

Best practice & research. Clinical rheumatology, 2013-06, Vol.27 (3), p.391-404

2013

Volltextzugriff (PDF)

Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis

British journal of dermatology (1951), 2017-01, Vol.176 (1), p.231-233

2017

Volltextzugriff (PDF)

Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument

British journal of dermatology (1951), 2010-03, Vol.162 (3), p.669-673

2010

Volltextzugriff (PDF)

The role of cytokines in the pathogenesis of cutaneous lupus erythematosus

Cytokine (Philadelphia, Pa.), 2015-06, Vol.73 (2), p.326-334

2015

Volltextzugriff (PDF)

Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists

British journal of dermatology (1951), 2017-10, Vol.177 (4), p.1086-1092

2017

Volltextzugriff (PDF)

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

British journal of dermatology (1951), 2008-10, Vol.159 (4), p.887-894

2008

Volltextzugriff (PDF)

The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists

British journal of dermatology (1951), 2017-02, Vol.176 (2), p.423-430

2017

Volltextzugriff (PDF)

Clinical outcome measures for cutaneous lupus erythematosus

Lupus, 2010-08, Vol.19 (9), p.1137-1143

2010

Volltextzugriff (PDF)

Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis

British journal of dermatology (1951), 2017-01, Vol.176 (1), p.262-264

2017

Volltextzugriff (PDF)

Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.949-954

2020

Volltextzugriff (PDF)

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study

British journal of dermatology (1951), 2021-10, Vol.185 (4), p.745-755

2021

Volltextzugriff (PDF)

A double‐blind, randomized, placebo‐controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.964-965

2019

Volltextzugriff (PDF)

Itch in dermatomyositis: the role of increased skin interleukin‐31

British journal of dermatology (1951), 2018-09, Vol.179 (3), p.669-678

2018

Volltextzugriff (PDF)

The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review

Seminars in arthritis and rheumatism, 2020-06, Vol.50 (3), p.458-462

2020

Volltextzugriff (PDF)

Cross‐cultural adaptations of health‐related quality of life measures

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.659-660

2019

Volltextzugriff (PDF)

Bullous pemphigoid burden of disease, management and unmet therapeutic needs

Journal of the European Academy of Dermatology and Venereology, 2024-09

2024

Volltextzugriff (PDF)

The incidence of bullous pemphigoid continues to increase in England

British journal of dermatology (1951), 2021-01, Vol.184 (1), p.5-6

2021

Volltextzugriff (PDF)

1 – 25 von 255

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(228)
Mit Volltextzugriff
(197)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

The impact of skin damage due to cutaneous lupus on quality of life

Biological therapies in the treatment of cutaneous lupus erythematosus

TNF-α production in the skin

Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis

Importance of recognition and improved treatment for antimelanoma differentiation‐associated protein 5‐associated dermatomyositis

A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus

Cutaneous lupus erythematosus: Diagnosis and treatment

Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis

Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument

The role of cytokines in the pathogenesis of cutaneous lupus erythematosus

Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists

Clinical outcome measures for cutaneous lupus erythematosus

Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis

Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study

A double‐blind, randomized, placebo‐controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus

Itch in dermatomyositis: the role of increased skin interleukin‐31

The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review

Cross‐cultural adaptations of health‐related quality of life measures

Bullous pemphigoid burden of disease, management and unmet therapeutic needs

The incidence of bullous pemphigoid continues to increase in England

Suchergebnisse filtern